I
AMI patients undergoing primary percutaneous coronary intervention (PCI).
Methods

Patient Population and Inclusion Criteria
In our hospital, all patients with AMI are considered eligible for primary PCI. For the purpose of this study, blood samples for serum IL-10 levels of patients who underwent primary PCI were prospectively withdrawn into EDTA tubes in the cardiac catheterization room following vascular puncture. To circumvent other potential influences on the circulating level of IL-10, we excluded patients with a history of recent surgery or trauma during the preceding 2 months, renal insufficiency (creatinine >1.5 mg/dl), malignancy, febrile disorders, acute or chronic inflammatory disease at study enrollment time, autoimmune diseases with or without immunosuppressive therapy, or a prior myocardial infarction (MI) onset of <3 months. Thus, between November 2002 and April 2004, 250 consecutive patients of any age who presented with AMI of <12 h duration, and who underwent primary PCI were prospectively investigated and recruited.
Thirty subjects matched for age, gender, hypertension, diabetes mellitus, current smoking and hypercholesterolemia were assigned as the at-risk control group in the outpatient department. Additionally, 20 age-and gender-matched healthy volunteers were assigned as the healthy control group at our healthy clinic center. Informed consent was given by each study subject and the Institutional Review Committee on Human Research approved the study protocol.
Procedure and Protocol
A transradial artery approach using a 6-French arterial sheath was routinely used for treatment of AMI at our hospital unless the both hands Allen's test was positive. A 6-French Kimny guiding catheter (Boston Scientific, Scimed, Inc Maple Grove, MN, USA) wass used for diagnosis and primary PCI. Immediately after coronary angioplasty, left ventriculograms were recorded at 30-degree right anterior oblique and 60-degree left anterior oblique views. From May 2002, the PercuSurge GuardWire™ device (Medtronic AVE) was used for consecutive patients presenting with AMI (<12 h duration). Enrollment and exclusion criteria and the procedure of using PercuSurge have been previously described in details. 15 At the beginning of this study tirofiban loading dosage (20 g/kg of body weight) was administered to patients upon presentation in the emergency room, followed by a maintenance infusion of 0.15 g·kg -1 ·min -1 for 18-24 h. However, tirofiban therapy was subsequently withheld because it was found not to provide any additional benefit to AMI patients who underwent primary PCI. 16 Therefore; only 39 (18.4%) of the patients received tirofiban therapy. Clopidogrel (300 mg loading dose before stenting, then 75 mg/day) was given to patients undergoing primary stenting. Aspirin (100 mg orally once a day) was given indefinitely to each patient. Other commonly prescribed drugs were angiotensin-converting enzyme inhibitors, -blockers, isornitrate and diuretics.
Blood Sampling and Laboratory Investigations
Blood samples were obtained once: from the healthy volunteers during healthy clinic examination, and from the at-risk control subjects in the outpatient department. Venous blood was withdrawn from the antecubital vein into EDTA tubes. After centrifugation, aliquots of the samples were stored at -80°C before assay for IL-10. White blood cell (WBC) count and biochemical measurements were done using standard laboratory methods.
Plasma IL-10 was measured by duplicated determination with a commercially available ELISA method (B & D systems, Inc Minneapolis, MN, USA). The lower detection limit is 5 pg/ml. The intra-individual variability of IL-10 levels was assessed in study patients and both control groups. The mean intra-assay coefficients of variance were all less than 4.0%. High-sensitivity CRP (hs-CRP) was measured by immunonephelometry using the BN™ system (Dade Behring Inc Newark, DE, USA). The lower detection limit is <0.15 mg/L. The intra-individual variability of serum hs-CRP levels was assessed in the study patients and both control groups and the mean intra-assay coefficient of variance was 3.1%, 2.9%, and 3.3%, respectively.
Definitions and Data Collection
AMI was defined as the presence of typical chest pain for more than 30 min with ST-se >1 mm in 2 or more consecutive precordial or inferior leads. Unsuccessful reperfusion was defined as failure to achieve normal blood flow after PCI (≤Thrombolysis In Myocardial Infarction (TIMI)-2 flow) of the infarct-related artery. Reperfusion time was defined as the time from chest pain onset to the first balloon inflation. Detailed in-hospital and follow-up data, including age, sex, coronary risk factors, serial MB fraction of creatine kinase (CK-MB) levels, WBC counts, creatinine level, Killip score on admission, severity of congestive heart failure (CHF), angiographic findings and number of diseased vessels were collected prospectively and entered into a computerized database.
Statistical Analysis
Data are expressed as mean ± SD. Categorical variables were compared using Chi-square or Fisher's exact test. Continuous variables between 2 groups were analyzed by the Wilcoxon's rank sum test. Continuous variables among 3 groups were analyzed by 1-way ANOVA or KruskalWallis test, followed by multiple comparison procedure with the Wilcoxon's rank sum test and Bonferroni's correction. Discriminate analysis was used to discover the most sensitive and specific cut-off value of IL-10 level for predicting 30-day mortality. Statistical analysis was performed using SAS statistical software for Windows version 8.2 (SAS institute, Cary, NC, USA). A value of p<0.05 was considered statistically significant. (Table 1 ) Table 1 summarizes the baseline characteristics of the AMI patients, at-risk control subjects and healthy control subjects. There was no significant difference among the 3 groups for age and gender, nor between AMI patients and at-risk control subjects for coronary artery disease risk factors. However, the hs-CRP level, WBC count and IL-10 levels were significantly higher in the AMI patients than in the at-risk control and healthy control subjects. Additionally, the IL-10 level was significantly higher in the at-risk control subjects than in the healthy control subjects. (Table 2) A serum IL-10 level of ≥30 pg/ml was the most powerful cut-off value identified by the discriminating test for predicting 30-day mortality, with a sensitivity of 83.8% and a specificity of 91.6%. Thus, patients with a plasma IL-10 level ≥30 pg/ml were classified as the high IL-10 group (Group 1) and those with a plasma IL-10 level <30 pg/ml were assigned to the low IL-10 group (Group 2).
Results
Baseline Characteristics of Study Group
There were no differences with regard to age, gender, cardiovascular risk factors, previous MI, previous stroke, incidence of anterior wall MI or the peak level of CK-MB between Groups 1 and 2. Additionally, there were no significant difference with regard to the incidence of multivessel disease, mean reperfusion time, successful reperfusion, frequency of using the PercuSurge device, use of tirofiban, or stenting between Groups 1 and 2. However, compared with Group 2, Group 1 had significantly more incidence of cardiogenic shock, more advanced CHF (defined as New York Heart Association Functional Classification ≥3), lower left ventricular ejection fraction (LVEF), higher WBC count, increased serum level of IL-10 and higher 30-day mortality. Table 3 presents the results of univariate analysis of factors associated with 30-day mortality. The most significant factors among these variables were high IL-10 level (≥30 pg/ml), cardiogenic shock, LVEF ≤50%, and advanced CHF. Female gender, peak CK-MB, serum level of hs-CRP, WBC count, multivessel disease and anterior wall MI were significantly related to an increased incidence of 30-day mortality, whereas successful reperfusion was associated with decreased 30-day mortality.
Determinants of 30-Day Mortality
Multiple stepwise logistic regression analysis (Table 4 ) of all the univariate significant factors shown in Table 3 revealed that IL-10 level and LVEF <50% are the strongest independent predictors of 30-day mortality. Additionally, unsuccessful reperfusion and WBC count were also independently predictive of 30-day mortality.
Discussion
The present study, which is the largest and also the first cohort study to evaluate the impact of circulating levels of the antiinflammatory cytokine IL-10 in patients with ST-se AMI undergoing primary PCI, has several striking clinical implications. First, the circulating level of IL-10 was remarkably higher in the study patients than in either of the control groups, and was significantly higher in the at-risk control group than in the healthy control subjects. These findings further support those from previous studies that antiinflammatory activity is different in various clinical settings. 14, 17, 18 Second, in contrast to a recent study finding that emphasized the association of a lower IL-10 level with poor prognostic clinical outcomes in patients with non ST-se ACS, 14, 17 our finding indicated that a high circulating level of IL-10 was strongly and independently predictive of 30-day mortality in patients with ST-se AMI undergoing primary PCI. Third, the results of this study confirmed previous observations that low LVEF, 18 unsuccessful reperfusion 19, 20 and high WBC count 22, 23 are predictive of unfavorable clinical outcomes in AMI patients. The present study, therefore, further strengthens the relevance of these 3 clinical relevant factors on untoward clinical outcomes following AMI.
Another important finding of this study is that the circulating level of IL-10 was substantially higher in the AMI patients than in either the at-risk or normal control subjects. This finding is supported by a prior small study 18 that showed elevated circulating levels of IL-10 in patients with AMI. We remain uncertain about when and how fast the IL-10 is released into the circulation following AMI. Markedly and rapidly elevated circulating inflammatory cytokines, inflammatory protein, and WBC counts have been identified following AMI. 2, 3, 5, 7, 22, 23 Additionally, it is well recognized that the inflammatory response is systemic. 2, 3, 6, 22, 23 Moreover, compared with the baseline IL-10 level of the at-risk control subjects, and based on previous observational studies, 14, 17 we suggest that the circulating level of this antiinflammatory cytokine is rapidly and markedly increased immediately following AMI, as a feedback loop, in order to suppress an acute and over-reactive inflammatory process. Previous studies have demonstrated that the circulating level of IL-10 rapidly increases following AMI. 18, 24 Another study suggested that thrombus played a role in inducing IL-10 expression. 13 Accordingly, our suggestion, based on our findings, is further supported by these previous studies. 2, 3, 6, 9, [22] [23] [24] Data to address the prognostic value of the circulating level of IL-10 in ST-se AMI patients undergoing primary PCI are not available. The most important finding in the present study is that a high circulating level of IL-10 was a major independent predictor of increased 30-day mortality. Surprisingly, 1 previous study demonstrated that elevated serum IL-10 levels are associated with a more favorable prognosis in patients with non-ST-se ACS. 14 However, our finding is supported by another prior small study 18 that showed a positive correlation between the circulating level of IL-10 and early death in patients after AMI. Therefore, we remain uncertain as to why there is such a discrepancy between our study and the previous finding. 14 However, the clinical settings were markedly different, which might help to explain the inconsistence between these 2 studies. In the present study, patients with ST-se AMI may have had significantly higher peak levels of CK-MB than in the patients with non-ST-se ACS. 14 Recently, we found that myocardial necrosis elicits an acute inflammatory response. 19 Additionally, ST-se AMI is associated with a high incidence of cardiogenic shock and advanced CHF, which would accentuate an acute and vigorous inflammatory response. Furthermore, the circulating levels of IL-10 in AMI patients has been identified as positively correlating with pulmonary capillary wedge pressure on admission and negatively correlating with the cardiac index. 18 However, non-ST-se ACS associated with low incidence of cardiogenic shock and advanced CHF, as in the previous study, 14 would reflect only a chronic persistent and relatively gentle inflammatory process. Additionally, other previous studies have demonstrated that rapidly and markedly increased circulating levels of inflammatory cytokines and WBC count occurs following AMI. 22, 23, 25, 26 These inflammatory mediators, which elicited an over-reactive response systemically, are harmful to AMI patients. [25] [26] [27] Moreover, convincing evidence shows that a proper balance between pro-and anti-inflammatory cytokines is necessary for regulating an adequate immune response. 1, 4 Perhaps these findings 1, 4, 18, 22, 23, [25] [26] [27] can explain why a high circulating level of IL-10, as an index of the antiinflammatory response, and WBC count, as an index of the inflammatory response, were independently predictive 30-day mortality in the present study. Accordingly, we suggest that an elevated circulating IL-10 level is a marker of the antiinflammatory process for AMI, and is directly correlated with the severity of the clinical course following AMI.
Another important finding in the present study was that low LVEF was a major independent predictor of 30-day mortality. Recently, we found that low LVEF was strongly associated with 30-day mortality and untoward clinical outcomes in the clinical setting of ST-se AMI undergoing primary PCI. 19, 28 Therefore, the results of this present study strengthen the observation of our recent studies. 19, 28 A link between unsuccessful reperfusion and unfavorable clinical outcomes has been well recognized by previous studies. 15, 16, 19, 20, 29 In our study, we found that final TIMIflow ≤2 was independently predictive of 30-day death. Accordingly, our finding further reinforce the findings of previous studies. 15, 16, 19, 20, 29 
Study Limitations
First, without serial measurement of circulating IL-10 levels, we could not provide information regarding how early the circulating IL-10 was elevated, or how long the elevation of IL-10 persisted in our patients. Second, the effects of circulating IL-10 on long-term clinical outcomes were not part of the protocol, so these relationships did not extend beyond the 30-day clinical outcomes.
Conclusion
This study identified that the circulating level of IL-10 is a major independent predictor of 30-day mortality in patients with ST-se AMI undergoing primary PCI. Therefore, we suggest its use in conjunction with other early risk-stratification factors in assessing the prognosis of AMI patients.
